ORC ID , Arturo Fraga-Bau2, David Arias Ron3, Elena Alvarez-Rodriguez2, Pablo Vicente-Alba2, Javier Lago-Garma4, Ana I Rodriguez-Perez5">
  • Users Online: 1230
  • Home
  • Print this page
  • Email this page
REVIEW
Year : 2022  |  Volume : 17  |  Issue : 8  |  Page : 1652-1658

Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing


1 Department of Clinical Neurology, Hospital Alvaro Cunqueiro, University Hospital Complex, Vigo; Laboratory of Cellular and Molecular Neurobiology of Parkinson’s Disease, Research Center for Molecular Medicine and Chronic Diseases (CIMUS), IDIS, University of Santiago de Compostela, Santiago de Compostela, Spain
2 Department of Clinical Neurology, Hospital Alvaro Cunqueiro, University Hospital Complex, Vigo, Spain
3 Department of Clinical Oncology, University Hospital Complex, Ourense, Spain
4 Department of Endocrinology, Hospital Meixoeiro, University Hospital Complex, Vigo, Spain
5 Laboratory of Cellular and Molecular Neurobiology of Parkinson’s Disease, Research Center for Molecular Medicine and Chronic Diseases (CIMUS), IDIS, University of Santiago de Compostela, Santiago de Compostela; Networking Research Center on Neurodegenerative Diseases (CiberNed), Madrid, Spain

Correspondence Address:
Carmen M Labandeira
Department of Clinical Neurology, Hospital Alvaro Cunqueiro, University Hospital Complex, Vigo; Laboratory of Cellular and Molecular Neurobiology of Parkinson’s Disease, Research Center for Molecular Medicine and Chronic Diseases (CIMUS), IDIS, University of Santiago de Compostela, Santiago de Compostela
Spain
Login to access the Email id

Source of Support: This work was supported by the Spanish Ministry of Health (PI17/00828 and Ciberned), Galician Government (XUGA, ED431C 2018/10, ED431G/05) and FEDER (Regional European Development Fund), all to AIRP, Conflict of Interest: None


DOI: 10.4103/1673-5374.332122

Rights and Permissions

In the last decade, attention has become greater to the relationship between neurodegeneration and abnormal insulin signaling in the central nervous system, as insulin in the brain is implicated in neuronal survival, plasticity, oxidative stress and neuroinflammation. Diabetes mellitus and Parkinson’s disease are both aging-associated diseases that are turning into epidemics worldwide. Diabetes mellitus and insulin resistance not only increase the possibility of developing Parkinson’s disease but can also determine the prognosis and progression of Parkinsonian symptoms. Today, there are no available curative or disease modifying treatments for Parkinson’s disease, but the role of insulin and antidiabetic medications in neurodegeneration opens a door to treatment repurposing to fight against Parkinson’s disease, both in diabetic and nondiabetic Parkinsonian patients. Furthermore, it is essential to comprehend how a frequent and treatable disease such as diabetes can influence the progression of neurodegeneration in a challenging disease such as Parkinson’s disease. Here, we review the present evidence on the connection between Parkinson’s disease and diabetes and the consequential implications of the existing antidiabetic molecules in the severity and development of Parkinsonism, with a particular focus on glucagon-like peptide-1 receptor agonists.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed300    
    Printed0    
    Emailed0    
    PDF Downloaded46    
    Comments [Add]    

Recommend this journal